Man, Kee-MingKee-MingManLee, Sing-OngSing-OngLeeLu, Chueng-HeChueng-HeLuWong, Chih-ShungChih-ShungWongWEI-ZEN SUN2023-12-112023-12-112023-03-01https://scholars.lib.ntu.edu.tw/handle/123456789/637674The NALDEBAIN® has been available since 2017, and high incidence of injection reactions in the phase 3 study has been reported. Since the first year in the market, the injection site reactions were still the majority of adverse drug reactions (ADRs) in pharmacovigilance reports. The new intramuscular (IM) instruction and package was introduced in the middle of 2018. In this retrospective study, we analyzed the pharmacovigilance data and published postmarketing studies to investigate the impact of IM injection-related reactions in Taiwan between the period of 2017-2022.eninjection site reactions; intramuscular injection; nalbuphinejournal article10.6859/aja.202303_61(1).0002371606632-s2.0-85164210088https://api.elsevier.com/content/abstract/scopus_id/85164210088